Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review

Human Reproduction Update

Volumn 8, Issue 6, 2002, Pages 559-577

  Delvinge, Annick ^a   Rozenberg, Serge ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Coasting; IVF; OHSS; Prevention; Treatment

Indexed keywords

ALBUMIN; ANTIINFLAMMATORY AGENT; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; CORTICOSTEROID DERIVATIVE; FOLLITROPIN; GLUCOCORTICOID; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; HETASTARCH; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; METFORMIN; OCTREOTIDE; PROGESTERONE; RECOMBINANT LUTEINIZING HORMONE;

ADULT; ALLERGIC REACTION; CAUTERIZATION; CRYOPRESERVATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOMETRIUM; FEMALE; FEMALE INFERTILITY; FEVER; HUMAN; IATROGENIC DISEASE; INFECTION; LOW DRUG DOSE; LUTEAL PHASE; LUTEOLYSIS; MACROMOLECULE; NAUSEA; OOCYTE; OVARY CYCLE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REVIEW; VAPORIZATION; VOMITING; EMBRYO; INFERTILITY; MEDLINE; OVARY POLYCYSTIC DISEASE; RISK FACTOR;

ADULT; CHORIONIC GONADOTROPIN; CRYOPRESERVATION; EMBRYO; FEMALE; HUMANS; INFERTILITY; LUTEAL PHASE; MEDLINE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; RISK FACTORS;

EID: 0036865059     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/8.6.559     Document Type: Review

References (190)

1. Abdalla, H.I., Ah-Moye, M., Brinsden, P., Howe, D.L., Okonofua, F., Craft, I. (1987) The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertil. Steril., 48, 958-963.
2. Abdel Gadir, A., Mowafi, R.S., Alnaser, H.M., Alrashid, A.H., Alonezi, O.M. and Shaw, R.W. (1990) Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clin. Endocrinol. (Oxf.), 33, 585-592.
3. Aboulghar, M.A., Mansour, R.T., Serour, G.I., Elattar, I. and Amin, Y. (1992) Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome. J. Assist. Reprod. Genet., 9, 238-243.
4. Aboulghar, M.A., Mansour, R.T., Serour, G.I., Ramzy, A.M. and Amin, Y.M. (1997) Oocyte quality in patients with severe ovarian hyperstimulation syndrome. Fertil. Steril., 68, 1017-1021.
5. Aboulghar, M.A., Mansour, R.T., Serour, G.I., Amin, Y.M., Sattar, M.A. and Elattar, E. (1998) Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. Fertil. Steril., 69 (3 Suppl. 2), 72S-75S.
6. Aboulghar, M.A., Mansour, R.T., Serour, G.I., Rhodes, C.A. and Amin, Y.M. (2000) Reduction of human menopausal gonadotropin dose before coasting prevents severe ovarian hyperstimulation syndrome with minimal cycle cancellation. J. Assist. Reprod. Genet., 17, 298-301.
7. Abramov, Y., Barak, V., Nisman, B. and Schenker, J.G. (1997) Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil. Steril., 67, 261-265.
8. Abramov, Y., Elchalal, U. and Schenker, J.G. (1999) Severe OHSS. An 'epidemic' of severe OHSS: a price to pay? Hum. Reprod., 14, 2181-2185.
9. Adams, J., Franks, S., Polson, D.W., Mason, H.D., Abdulwahid, N., Tucker, M., Morris, D.V., Price, J. and Jacobs, H.S. (1985) Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet, 2, 1375-1379.
10. Albano, C., Smitz, J., Camus, M., Riethmuller-Winzen, H., Van Steirteghem, A. and Devroey, P. (1997) Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril., 67, 917-922.
11. Al-Inany, H. and Aboulghar, M. (2002) GnRH antagonist in assisted reproduction: a Cochrane review. Hum. Reprod., 17, 874-885.
12. Amso, N.N. (1995) Potential health hazards of assisted reproduction. Problems facing the clinician. Hum. Reprod., 10, 1628-1630.
13. Amso, N.N., Ahuja, K.K., Morris, N. and Shaw, R.W. (1990) The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos. Fertil. Steril., 53, 1087-1090.
14. Amso, N.N., Shaw, R.W., Ahuja, K.K. and Morris, N. (1991) Prevention of ovarian hyperstimulation syndrome. Fertil. Steril., 55, 220-221.
15. Araujo, E., Jr, Bernardini, L., Frederick, J.L., Asch, R.H. and Balmaceda, J.P. (1994) Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction. J. Assist. Reprod. Genet., 11, 74-78.
16. Armar, N.A., McGarrigle, H.H., Honour, J., Holownia, P., Jacobs, H.S. and Lachelin, G.C. (1990) Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil. Steril., 53, 45-49.
17. Asch, R.H., Li, H.P., Balmaceda, J.P., Weckstein, L.N. and Stone, S.C. (1991) Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum. Reprod., 6, 1395-1399.
18. Asch, R.H., Ivery, G., Goldsman, M., Frederick, J.L., Stone, S.C. and Balmaceda, J.P. (1993) The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum. Reprod., 8, 1015-1020.
19. Awonuga, A.O., Pittrof, R.J., Zaidi, J., Dean, N., Jacobs, H.S. and Tan, S.L. (1996) Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate. J. Assist. Reprod. Genet., 13, 401-406.
20. Balasch, J., Tur, R., Creus, M., Buxaderas, R., Fabregues, F., Ballesca, J.L., Barri, P.N. and Vanrell, J.A. (1994) Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. Gynecol. Endocrinol., 8, 7-12.
21. Balen, A. (1999) Ovarian hyperstimulation syndrome. Hum. Reprod., 14, 1138-1139.
22. Balen, A.H., Braat, D.D., West, C., Patel, A. and Jacobs, H.S. (1994) Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. Hum. Reprod., 9, 1563-1570.
23. Benadiva, C.A., Davis, O., Kligman, I., Moomjy, M., Liu, H.C. and Rosenwaks, Z. (1997) Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil. Steril., 67, 724-727.
24. Ben-Arie, A., Weissman, A. and Shoham, Z. (1996) Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. Hum. Reprod., 11, 1146-1148.
25. Ben-Rafael, Z., Orvieto, R., Dekel, A., Peleg, D. and Gruzman, C. (1995) Intravenous albumin and the prevention of severe ovarian hyperstimulation syndrome. Hum. Reprod., 10, 2750-2752.
26. Ben-Shlomo, L, Geslevich, J. and Shalev, E. (2001) Can we abandon routine evaluation of serum estradiol levels during controlled ovarian hyperstimulation for assisted reproduction? Fertil. Steril., 76, 300-303.
27. Bettendorf, G. and Lindner, C. (1987) The ovarian hyperstimulation syndrome. Horm. Metab. Res., 19, 519-522.
28. Blankstein, J., Shalev, J., Saadon, T., Kukia, E.E., Rabinovici, J., Pariente, C., Lunenfeld, B., Serr, D.M. and Mashiach, S. (1987) Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil. Steril., 47, 597-602.
29. Bodis, J., Torok, A. and Tinneberg, H.R. (1997) LH/FSH ratio as a predictor of ovarian hyperstimulation syndrome. Hum. Reprod., 12, 869-870.
30. Brinsden, P.R., Wada, I., Tan, S.L., Balen, A. and Jacobs, H.S. (1995) Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br. J. Obstet. Gynaecol., 102, 767-772.
31. Buvat, J., Buvat-Herbaut, M., Marcolin, G., Dehaene, J.L., Verbecq, P. and Renouard, O. (1989) Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. Fertil. Steril., 52, 553-559.
32. Buyalos, R.P. and Lee, C.T. (1996) Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. Fertil. Steril., 65, 1-10.
33. Casper, R.F. (1996) Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? Hum. Reprod., 11, 1144-1146.
34. Caspi, E., Ron-El, R., Golan, A., Nachum, H., Herman, A., Soffer, Y. and Weinraub, Z. (1989) Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins. Fertil. Steril., 51, 95-99.
35. Check, J.H., Wu, C.H., Gocial, B. and Adelson, H.G. (1985a) Severe ovarian hyperstimulation syndrome from treatment with urinary follicle-stimulating hormone: two cases. Fertil. Steril., 43, 317-319.
36. Check, J.H., Goldberg, B.B., Kurtz, A., Adelson, H.G. and Dietterich, C. (1985b) Serum estradiols versus pelvic sonography in monitoring HMG therapy. Int. J. Fertil., 30, 61-63.
37. Chen, C.D., Wu, M.Y., Yang, J.H., Chen, S.U., Ho, H.N. and Yang, Y.S. (1997) Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Fertil. Steril., 68, 287-291.
38. Cluroe, A.D. and Synek, B.J. (1995) A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology, 27, 344-346.
39. Costabile, L., Unfer, V., Manna, C., Gerli, S., Rossetti, D. and Di Renzo, G.C. (2000) Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome. Gynecol. Obstet. Invest., 50, 182-185.
40. Crooke, A.C. (1970) Induction of ovulation with gonadotrophins. Br. Med. Bull., 26, 17-21.
41. Danninger, B., Brunner, M., Obruca, A. and Feichtinger, W. (1996) Prediction of ovarian hyperstimulation syndrome by ultrasound volumetric assessment [corrected] of baseline ovarian volume prior to stimulation. Hum. Reprod, 11, 1597-1599.
42. Daya, S. (2002) Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil. Steril., 77, 711-714.
43. Delvigne, A. and Rozenberg, S. (2001) Preventive attitude of physicians to avoid OHSS in IVF patients. Hum. Reprod., 16, 2491-2495.
44. Delvigne, A. and Rozenberg, S. (2002) A systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in in vitro fertilisation patients. Hum. Reprod Update, 8, 291-296.
45. Delvigne, A., Demoulin, A., Smitz, J., Donnez, J., Koninckx, P., Dhont, M., Englert, Y., Delbeke, L., Darcis, L., Gordts, S. et al. (1993a) The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum. Reprod., 8, 1353-1360.
46. Delvigne, A., Dubois, M., Battheu, B., Bassil, S., Meuleman, C., De Sutter, P., Rodesch, C., Janssens, P., Remacle, P., Gordts, S. et al. (1993b) The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum. Reprod, 8, 1361-1366.
47. Delvigne, A., Vandromme, J., Demeestere, I. and Leroy, F. (1997) Unpredictable cases of complicated ovarian hyperstimulation in IVF. Int. J. Fertil. Womens Med., 42, 268-270.
48. Delvigne, A., Kostyla, K., De Leener, A., Lejeune, B., Cantiniaux, B., Bergmann, P. and Rozenberg, S. (2002a) Metabolic characteristics of OHSS patients who developed ovarian hyperstimulation syndrome. Hum. Reprod., 17, 1194-1196.
49. Delvigne, A., Manigart, Y., Kostyla, K., Murillo, D., Van Hoeck, J., Rozenberg, S. (2002b) Oocyte quality after coasting for ovarian hyperstimulation syndrome prevention. Hum. Reprod, 17 (Abstract book 1, P450), 153.
50. Devroey, P. (2000) GnRH antagonists. Fertil. Steril., 73, 15-17.
51. Diamond, M.P. and Wentz, A.C. (1986) Ovulation induction with human menopausal gonadotropins. Obstet. Gynecol. Surv., 41, 480-490.
52. Doldi, N., Destefani, A., Gessi, A., Grossi, D. and Ferrari, A. (1999) Human albumin enhances expression of vascular endothelial growth factor in cultured human luteinizing granulosa cells: importance in ovarian hyperstimulation syndrome. Hum. Reprod, 14, 1157-1159.
53. Donesky, B.W. and Adashi, E.Y. (1995) Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy. Fertil. Steril., 63, 439-463.
54. Dor, J., Shulman, A., Levran, D., Ben-Rafael, Z., Rudak, E. and Mashiach, S. (1990) The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: a comparison of results with those of patients with tubal infertility. Hum. Reprod., 5, 816-818.
55. Dunaif, A., Scott, D., Finegood, D., Quintana, B. and Whitcomb, R. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 81, 3299-3306.
56. Egbase, P.E., Makhseed, M., Al Sharhan, M. and Grudzinskas, J.G. (1997) Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Hum. Reprod., 12, 2603-2606.
57. Egbase, P., Al-Awadi, S., Al-Sharhan, M. and Grudzinskas, J.G. (1998) Unilateral ovarian diathermy prior to successful in vitro fertilisation: a strategy to prevent recurrence of ovarian hyperstimulation syndrome? J. Obstet. Gynecol., 18, 171-173.
58. Egbase, P.E., Sharhan, M.A. and Grudzinskas, J.G. (1999) Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum. Reprod., 14, 1421-1425.
59. Elchalal, U. and Schenker, J.G. (1997) The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Hum. Reprod., 12, 1129-1137.
60. El-Sheikh, M.M., Hussein, M., Fouad, S., El-Sheikh, R., Bauer, O. and Al-Hasani, S. (2001) Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease. Eur. J. Obstet. Gynecol. Reprod. Biol., 94, 245-249.
61. Emperaire, J.C. and Ruffie, A. (1991) Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum. Reprod, 6, 506-510.
62. Enskog, A., Henriksson, M., Unander, M., Nilsson, L. and Brannstrom, M. (1999) Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil. Steril., 71, 808-814.
63. Enskog, A., Nilsson, L. and Brannstrom, M. (2000) Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. Hum. Reprod., 15, 532-538.
64. Fauser, B.C., de Jong, D., Olivennes, F., Wramsby, H., Tay, C., Itskovitz-Eldor, J. and van Hooren, H.G. (2002) Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J. Clin. Endocrinol. Metab., 87, 709-715.
65. Fedorcsak, P., Dale, P.O., Storeng, R., Tanbo, T. and Abyholm, T. (2001) The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum. Reprod., 16, 1086-1091.
66. Ferraretti, A.P., Gianaroli, L., Diotallevi, L., Festi, C. and Trounson, A. (1992) Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum. Reprod., 7, 180-183.
67. Ferraretti, A.P., Gianaroli, L., Magli, C., Fortini, D., Selman, H.A. and Feliciani, E. (1999) Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum. Reprod., 14, 1457-1460.
68. Filicori, M., Flamigni, C., Meriggiola, M.C., Ferrari, P., Michelacci, L., Campaniello, E., Valdiserri, A. and Cognigni, G. (1991) Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders. J. Clin. Endocrinol. Metab., 72, 965-972.
69. Fluker, M.R., Hooper, W.M. and Yuzpe, A.A. (1999) Withholding gonadotropins ('coasting') to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. Fertil. Steril., 71, 294-301.
70. Forman, R.G., Frydman, R., Egan, D., Ross, C. and Barlow, D.H. (1990) Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil. Steril., 53, 502-509.
71. French National Register On In vitro Fertilization 1996 Report (1996) Contracept. Fertil. Sex., 25, 7-8, 499-502.
72. Friedman, C.I., Schmidt, G.E., Chang, F.E. and Kim, M.H. (1984) Severe ovarian hyperstimulation following follicular aspiration. Am. J. Obstet. Gynecol., 150, 436-437.
73. Fukaya, T., Murakami, T., Tamura, M., Watanabe, T., Terada, Y. and Yajima, A. (1995) Laser vaporization of the ovarian surface in polycystic ovary disease results in reduced ovarian hyperstimulation and improved pregnancy rates. Am. J. Obstet. Gynecol., 173, 119-125.
74. Fulghesu, A.M., Villa, P., Pavone, V., Guido, M., Apa, R., Caruso, A., Lanzone, A., Rossodivita, A. and Mancuso, S. (1997) The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 82, 644-648.
75. Gerris, J. and Van Royen, E. (2000) Avoiding multiple pregnancies in ART: a plea for single embryo transfer. Hum. Reprod., 15, 1884-1888.
76. Gerris, J., De Vits, A., Joostens, M. and Van Royen, E. (1995) Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10 000 IU). Hum. Reprod., 10, 56-62.
77. Gjonnaess, H. (1984) Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil. Steril., 41, 20-25.
78. Gokmen, O., Ugur, M., Ekin, M., Keles, G., Turan, C. and Oral, H. (2001) Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol., 96, 187-192.
79. Golan, A., Ron-El, R., Herman, A., Weinraub, Z., Soffer, Y. and Caspi, E. (1989) Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. Fertil. Steril., 50, 912-916.
80. Golan, A., Ron-El, R., Herman, A., Soffer, Y., Weinraub, Z. and Caspil E. (1989) Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv., 44, 430-440.
81. Gonen, Y., Balakier, H., Powell, W. and Casper, R.F. (1990) Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J. Clin. Endocrinol. Metab., 71, 918-922.
82. Gonen, Y., Powell, W.A. and Casper, R.F. (1991) Effect of follicular aspiration on hormonal parameters in patients undergoing ovarian stimulation. Hum. Reprod., 6, 356-358.
83. Graf, M.A., Fischer, R., Naether, O.G., Baukloh, V., Tafel, J. and Nuckel, M. (1997) Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. Hum. Reprod., 12, 2599-2602.
84. Greenblatt, E.M. and Casper, R.F. (1993) Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. Fertil. Steril., 60, 766-770.
85. Gustafson, O., Carlstrom, K. and Nylund, L. (1992) Androstenedione as a predictor of ovarian hyperstimulation syndrome. Hum. Reprod., 7, 918-921.
86. Halme, J., Toma, S.K. and Talbert, L.M. (1995) A case of severe ovarian hyperstimulation in a healthy oocyte donor. Fertil. Steril., 64, 857-859.
87. Hammerstein, J. (1967) Risks of ovarian overstimulation by administration of clomiphene and gonadotropins for ovulation stimulation. Geburtshilfe Frauenheilkd., 27, 1125-1151.
88. Hamilton-Fairley, D., Kiddy, D., Watson, H., Sagle, M. and Franks, S. (1991) Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum. Reprod, 6, 1095-1099.
89. Hampton, H.L., Whitworth, N.S. and Cowan, B.D. (1991) Gonadotropin-releasing hormone agonist (leuprolide acetate) induced ovarian hyperstimulation syndrome in a woman undergoing intermittent hemodialysis. Fertil. Steril., 55, 429-431.
90. Hancock, K.W., Stitch, S.R., Oakey, R.E., Scott, J.S., Levell, M.J. and Ellis, F.R. (1970) Ovulation stimulation. Problems of prediction of response to gonadotrophins. Lancet, 2, 482-485.
91. Haning, R.V., Jr, Austin, C.W., Carlson, I.H., Kuzma, D.L., Shapiro, S.S. and Zweibel, W.J. (1983) Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil. Steril., 40, 31-36.
92. Hazout, A., Porchier, J. and Frydman, R.. (1984) Une alternative à la réduction embryonnaire: la réduction embryonnaire. Gynecologie, 66, 220-224.
93. Hedon, B., Out, H.J., Hugues, J.N., Camier, B., Cohen, J., Lopes, P., Zorn, J.R., van der Heijden, B. and Coelingh Bennink, H.J. (1995) Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: A prospective, randomized, assessor-blind, multicentre trial. Hum. Reprod., 10, 3102-3106.
94. Herman, A., Ron-El, R., Golan, A., Raziel, A., Soffer, Y. and Caspi, E. (1990) Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins. Fertil. Steril., 53, 92-96.
95. Hughes, E., Collins, J. and Vandekerckhove, P. (2000) Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst. Rev., 2000 (2), CD000087.
96. Imoedemhe, D.A., Chan, R.C., Sigue, A.B., Pacpaco, E.L. and Olazo, A.B. (1991) A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme. Hum. Reprod., 6, 1088-1091.
97. Imoedemhe, D., Chan, R. and Pacpaco, E. (1999) Preventing OHSS in at-risk patients: evidence from a long-term prospective study. Hum. Reprod., 14 (Abstract Book 1), 102-103.
98. Isik, A.Z. and Vicdan, K. (2001) Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol., 97, 208-212.
99. Isik, A.Z., Gokmen, O., Zeyneloglu, H.B., Kara, S., Keles, G. and Gulekli, B. (1996) Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol., 70, 179-183.
100. Itskovitz-Eldor, J., Levron, J. and Kol, S. (1993) Use of gonadotropin-releasing hormone agonist to cause ovulation and prevent the ovarian hyperstimulation syndrome. Clin. Obstet. Gynecol., 36, 701-710.
101. Jain, T., Harlow, B.L. and Hornstein, M.D. (2002) Insurance coverage and outcomes of in vitro fertilization. N. Engl. J. Med., 347, 661-666.
102. Jaroudi, K.A., Hollanders, J.M., Sieck, U.V., Roca, G.L., El-Nour, A.M. and Coskun, S. (1997) Pregnancy after transfer of embryos which were generated from in-vitro matured oocytes. Hum. Reprod., 12, 857-859.
103. Kamat, BR., Brown, L.F., Manseau, E.J., Senger, DR. and Dvorak, H.F. (1995) Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am. J. Pathol., 146, 157-165.
104. Karam, K.S., Taymor, M.L. and Berger, M.J. (1973) Estrogen monitoring and the prevention of ovarian overstimulation during gonadotropin therapy. Am. J. Obstet. Gynecol., 115, 972-977.
105. Khalaf, Y., Anderson, H., Taylor, A. and Braude, P. (2000) Two rare events in one patient undergoing assisted conception: empty follicle syndrome and ovarian hyperstimulation with the sole administration of a gonadotropin-releasing hormone agonist. Fertil. Steril., 73, 171-172.
106. Kistner, R.W. (1965) Induction of ovulation with clomiphene citrate (clomid). Obstet. Gynecol. Surv., 20, 873-900.
107. Koike, T., Araki, S., Ogawa, S., Minakami, H. and Sato, I. (1999) Does i.v. albumin prevent ovarian hyperstimulation syndrome? Hum. Reprod., 14, 1920.
108. Kol, S. and Itskovitz-Eldor, J. (2000) Severe OHSS: yes, there is a strategy to prevent it! Hum. Reprod, 15, 2266-2267.
109. Kol, S., Lewit, N. and Itskovitz-Eldor, J. (1996) Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Hum. Reprod, 11, 1143-1144.
110. König, E., Bussen, S., Sutterlin, M. and Steck, T. (1998) Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Hum. Reprod, 13, 2421-2424.
111. Kulikowski, M., Wolczynski, S., Kuczynski, W., Grochowski, D. and Szamatowicz, M. (1995) Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome. Gynecol. Endocrinol., 9, 97-102.
112. Laufer, N., DeCherney, A.H., Tarlatzis, B.C., Zuckerman, A.L., Polan, M.L., Dlugi, A.M., Graebe, R., Barnea, E.R. and Naftolin, F. (1984) Delaying human chorionic gonadotrophin administration in human menopausal gonadotrophin-induced cycles decreases successful in-vitro fertilization of human oocytes. Fertil. Steril., 42, 198-203.
113. Laufer, N., Grundfeld, L. and Garrisi, G.J. (1990) In vitro fertilization. In: Leibel, M.M. (ed.), Infertility: A Comprehensive Text. Appleton-Lange, Norwalk, CT, pp. 481-511.
114. Levy, T., Orvieto, R., Homburg, R., Peleg, D., Dekel, A. and Ben-Rafael, Z. (1996) Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient. Hum. Reprod, 11, 1177-1179.
115. Lewis, C.G., Warnes, G.M., Wang, X.J. and Matthews, C.D. (1990) Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling women. Fertil. Steril., 53, 1097-1099.
116. Lewit, N., Kol, S., Ronen, N. and Itskovitz-Eldor, J. (1996) does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome? Fertil. Steril., 66, 654-656.
117. Lipitz, S., Ben-Rafael, Z., Bider, D., Shalev, J. and Mashiach, S. (1991) Quintuplet pregnancy and third degree ovarian hyperstimulation despite withholding human chorionic gonadotrophin. Hum. Reprod, 6, 1478-1479.
118. Lyons, C.A., Wheeler, C.A., Frishman, G.N., Hackett, R.J., Seifer, D.B. and Haning, R.V., Jr (1994) Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum. Reprod., 9, 792-799.
119. MacDougall, M.J., Tan, S.L. and Jacobs, H.S. (1992) In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum. Reprod., 7, 597-600.
120. MacDougall, M.J., Tan, S.L., Balen, A. and Jacobs, H.S. (1993) A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum. Reprod., 8, 233-237.
121. Marci, R., Senn, A., Dessole, S., Chanson, A., Loumaye, E., De Grandi, P. and Germond, M. (2001) A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil. Steril., 75, 1131-1135.
122. Mathur, R.S., Akande, A.V., Keay, S.D., Hunt, L.P. and Jenkins, J.M. (2000) Distinction between early and late ovarian hyperstimulation syndrome. Fertil. Steril., 73, 901-907.
123. McArdle, C., Seibel, M., Hann, L.E., Weinstein, F. and Taymor, M. (1983) The diagnosis of ovarian hyperstimulation (OHS): the impact of ultrasound. Fertil. Steril., 39, 464-467.
124. McClure, N., Leya, J., Radwanska, E., Rawlins, R. and Haning, R.V., Jr (1992) Luteal phase support and severe ovarian hyperstimulation syndrome. Hum. Reprod., 7,758-764.
125. Moohan, J.M., Curcio, K., Leoni, M., Healy, D. and Hurley, V. (1997) Low intraovarian vascular resistance: a marker for severe ovarian hyperstimulation syndrome. Fertil. Steril., 67, 728-732.
126. Mordel, N. and Schenker, J.G. (1993) Gonadotrophin-releasing hormone agonist and ovarian hyperstimulation syndrome in assisted reproduction. Hum. Reprod, 8, 2009-2014.
127. Morris, R.S., Wong, I.L., Kirkman, E., Gentschein, E. and Paulson, R.J. (1995) Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum. Reprod, 10, 1355-1358.
128. Morris, R.S., Karande, V.C., Dudkiewicz, A., Morris, J.L. and Gleicher, N. (1999) Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. Fertil. Steril., 71, 452-456.
129. Mozes, M., Bogokowsky, H., Antebi, E., Lunenfeld, B., Rabau, E., Serr, D.M., David, A. and Salomy, M. (1965) Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet, 2, 1213-1215.
130. Mukherjee, T., Copperman, A.B., Sandler, B., Bustillo, M. and Grunfeld, L. (1995) Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilization and embryo transfer. Fertil. Steril., 64, 641-643.
131. Murad, N.M. (1998) Ultrasound or ultrasound and hormonal determinations for in vitro fertilization monitoring. Int. J. Gynaecol. Obstet., 63, 271-276.
132. Navot, D., Relou, A., Birkenfeld, A., Rabinowitz, R., Brzezinski, A. and Margalioth, E.J. (1988) Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am. J. Obstet. Gynecol., 159, 210-215.
133. Navot, D., Bergh, P.A. and Laufer, N. (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil. Steril., 58, 249-261.
134. Ndukwe, G., Thornton, S., Fishel, S., Dowell, K. and Aloum, M. (1997) Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin? Fertil. Steril., 68, 851-854.
135. Neveu, S., Hedon, B., Mares, P., Bringer, J., Arnal, F., Sultan, C., Cristol, O., Gilbert, F. and Humeau, C. (1987) IVF in polycystic ovary syndrome. Hum. Reprod., 2 (Suppl.1), 77.
136. Ng, E., Leader, A., Claman, P., Domingo, M. and Spence, J.E. (1995) Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Hum. Reprod, 10, 807-810.
137. Norman, R.J., Warnes, G.M., Wang, X., Kirby, C.A. and Matthews, C.D. (1991) Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles. Hum. Reprod, 6, 206-213.
138. Olivennes, F., Fanchin, R., Bouchard, P., Taieb, J. and Frydman, R. (1996) Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil. Steril., 66, 151-153.
139. Olivennes, F., Cunha-Filho, J.S., Fanchin, R., Bouchard, P. and Frydman, R. (2002) The use of GnRH antagonists in ovarian stimulation. Hum. Reprod., 17, 279-299.
140. Orvieto, R. and Ben-Rafael, Z. (1996) Prophylactic intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome. Hum. Reprod., 11, 460-461.
141. Orvieto, R., Dekel, A., Dicker, D., Bar-Hava, I. and Ben-Rafael, Z. (1995) A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. Fertil. Steril., 64, 860-862.
142. Orvieto, R., Abir, R., Kaplan, B., Bar-Hava, I. and Ben-Rafael, Z. (1999) The role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. A pilot experimental study. Clin. Exp. Obstet. Gynecol., 26, 98-99.
143. Padilla, S.L., Zamaria, S., Baramki, T.A. and Garcia, J.E. (1990) Abdominal paracentesis for the ovarian hyperstimulation syndrome with severe pulmonary compromise. Fertil. Steril., 53, 365-367.
144. Panay, N., Iammarrone, E., Zosmer, A., Tozer, A., Hussain, S. and Wilson, C. (1999) Does the prophylactic use of intravenous albumin prevent ovarian hyperstimulation syndrome? A randomized prospective study. Hum. Reprod., 14, (Abstract Book) 105.
145. Pattinson, H.A., Hignett, M., Dunphy, B.C. and Fleetham, JA. (1994) Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. Fertil. Steril., 62, 1192-1196.
146. Penzias, A.S. (2002) Luteal phase support. Fertil. Steril., 77, 318-323.
147. Queenan, J.T., Jr, Veeck, L.L., Toner, J.P., Oehninger, S. and Muasher, S.J. (1997) Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum. Reprod., 12, 1573-1576.
148. Rabinovici, J., Kushnir, O., Shalev, J., Goldenberg, M. and Blankstein, J. (1987) Rescue of menotrophin cycles prone to develop ovarian hyperstimulation. Br. J. Obstet. Gynaecol., 94, 1098-1102.
149. Rimington, M.R., Walker, S.M. and Shaw, R.W. (1997) The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum. Reprod., 12, 1443-1447.
150. Rizk, B. and Smitz, J. (1992) Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum. Reprod., 7, 320-327.
151. Salat-Baroux, J., Alvarez, S., Antoine, J.M., Cornet, D., Tibi, C., Plachot, M. and Mandelbaum, J. (1990) Treatment of hyperstimulation during in-vitro fertilization. Hum. Reprod., 5, 36-39.
152. Sauer, M.V. (2001) Defining the incidence of serious complications experienced by oocyte donors: a review of 1000 cases. Am. J. Obstet. Gynecol., 184, 277-278.
153. Schenker, J.G. and Ezra, Y. (1994) Complications of assisted reproductive techniques. Fertil. Steril., 61, 411-422.
154. Schenker, J.G. and Weinstein, D. (1978) Ovarian hyperstimulation syndrome: a current survey. Fertil. Steril., 30, 255-268.
155. Segal, S. and Casper, R.F. (1992) Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertil. Steril., 57, 1254-1258.
156. Seibel, M.M., McArdle, C., Smith, D. and Taymor, M.L. (1985) Ovulation induction in polycystic ovary syndrome with urinary follicle-stimulating hormone or human menopausal gonadotropin. Fertil. Steril., 43, 703-708.
157. Serour, G.I., Aboulghar, M., Mansour, R., Sattar, M.A., Amin, Y. and Aboulghar, H. (1998) Complications of medically assisted conception in 3,500 cycles. Fertil. Steril., 70, 638-642.
158. Shahata, M., Yang, D., al-Natsha, S.D. and al-Shawaf, T. (1994) Intravenous albumin and severe ovarian hyperstimulation. Hum. Reprod., 9, 2186.
159. Shaker, A., Zosmer, A. and Dean, N. (1996) Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertil. Steril., 65, 992-996.
160. Shalev, E., Geslevich, Y., Matilsky, M. and Ben-Ami, M. (1995a) Induction of pre-ovulatory gonadotrophin surge with gonadotrophin-releasing hormone agonist compared to pre-ovulatory injection of human chorionic gonadotrophins for ovulation induction in intrauterine insemination treatment cycles. Hum. Reprod., 10, 2244-2247.
161. Shalev, E., Giladi, Y., Matilsky, M. and Ben-Ami, M. (1995b) Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study. Hum. Reprod., 10, 1373-1376.
162. Sher, G., Salem, R., Feinman, M., Dodge, S., Zouves, C. and Knutzen, V. (1993) Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstet. Gynecol., 81, 1009-1011.
163. Shimon, I., Rubinek, T., Bar-Hava, I., Nass, D., Hadani, M., Amsterdam, A. and Harel, G. (2001) Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. J. Clin. Endocrinol. Metab., 86, 3635-3640.
164. Shoham, Z., Borenstein, R., Barash, A., Zalel, Y. and Insler, V. (1993) Prevention of ovarian hyperstimulation syndrome? Fertil. Steril., 60, 585.
165. Shoham, Z., Weissman, A., Barash, A., Borenstein, R., Schachter, M. and Insler, V. (1994) Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil. Steril., 62, 137-142.
166. Shoham, Z., Schachter, M., Loumaye, E., Weissman, A., MacNamee, M. and Insler, V. (1995) The luteinizing hormone surge - the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil. Steril., 64, 237-251.
167. Shulman, A. and Dor, J. (1997) In vitro fertilization treatment in patients with polycystic ovaries. J. Assist. Reprod. Genet., 14, 7-10.
168. Smitz, J., Camus, M., Devroey, P., Erard, P., Wisanto, A. and Van Steirteghem, A.C. (1990) Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization. Hum. Reprod., 5, 933-937.
169. Tal, J., Paz, B., Samberg, I., Lazaroun, N. and Scharf, M. (1985) Ultrasonographic and clinical correlates of metropin versus sequential clomiphene citrate: menotropin for induction of ovulation. Fertil. Steril., 44, 342.
170. Tan, S.L., Balen, A., el Hussein, E., Campbell, S. and Jacobs, H.S. (1992) The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. Fertil. Steril., 58, 378-383.
171. The European Recombinant LH Study Group (2001) Recombinant human luteinizing hormone is as effective as, but safer than, urinary human chorionic, gonadotrphin in inducing final follicular maturation and ovulation in in-vitro fertilization procedures; results of a multicenter double blind study. J. Clin. Endocrinol. Metab., 86, 2607-2616.
172. Thompson, C.R. and Hansen, L.M. (1970) Pergonal (menotropins): a summary of clinical experience in the induction of ovulation and pregnancy. Fertil. Steril., 21, 844-853.
173. Tibi, C., Alvarez, S., Cornet, D., Antoine, J.-M., Gomes, A.C. and Salat-Baroux, J. (1989) Prédiction des hyperstimulations ovariennes. Contracept. Fertil. Sex., 17, 751-752.
174. Tiitinen, A., Husa, L.M., Tulppala, M., Simberg, N. and Seppala, M. (1995) The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome. Br. J. Obstet. Gynaecol., 102, 326-329.
175. Todorow, S., Schricker, S.T., Siebzehnruebl, E.R., Neidhardt, B., Wildt, L. and Lang, N. (1993) von Willebrand factor: an endothelial marker to monitor in-vitro fertilization patients with ovarian hyperstimulation syndrome. Hum. Reprod, 8, 2039-2046.
176. Tozer, A.J., Al-Shawaf, T., Zosmer, A., Hussain, S., Wilson, C., Lower, A.M. and Grudzinskas, J.G. (2001) Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study. Hum. Reprod., 16, 91-95.
177. Tulandi, T., McInnes, R.A. and Arronet, G.H. (1984) Ovarian hyperstimulation syndrome following ovulation induction with human menopausal gonadotropin. Int. J. Fertil., 29, 113-117.
178. Ulug, U., Bahceci, M., Erden, H.F., Shalev, E. and Ben-Shlomo, I. (2002) The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum. Reprod., 17, 310-313.
179. Urman, B., Pride, S.M. and Yuen, B.H. (1992) Management of overstimulated gonadotrophin cycles with a controlled drift period. Hum. Reprod., 7, 213-217.
180. van der Meer, S., Gerris, J., Joostens, M. and Tas, B. (1993) Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome. Hum. Reprod, 8, 1628-1631.
181. Vande Wiele, R.L., Bogumil, J., Dyrenfurth, L, Ferin, M., Jewelewicz, R., Warren, M., Rizkallah, T. and Mikhail, G. (1970) Mechanisms regulating the menstrual cycle in women. Recent Prog. Horm. Res., 26, 63-103.
182. Vrtovec, H.M. and Tomazevic, T. (1995) Preventing severe ovarian hyperstimulation syndrome in an in vitro fertilization/embryo transfer program. Use of follicular aspiration after human chorionic gonadotropin administration. J. Reprod Med., 40, 37-40.
183. Wada, I., Matson, P.L., Burslem, R.W., Troup, S.A., Morrol, D., Smith, W. and Lieberman, B.A. (1991) Ovarian hyperstimulation syndrome in GnRH/hMG stimulated cycles for IVF or GIFT. J. Obstet. Gynecol., 11, 88-89.
184. Wada, I., Matson, P.L., Horne, G., Buck, P. and Lieberman, B.A. (1992a) Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome? Hum. Reprod, 7, 1090-1093.
185. Wada, I., Matson, P.L., Troup, S.A., Hughes, S., Buck, P. and Lieberman, B.A. (1992b) Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. Hum. Reprod., 7, 962-966.
186. Wada, I., Matson, P.L., Troup, S.A. and Lieberman, B.A. (1993a) Assisted conception using buserelin and human menopausal gonadotrophins in women with polycystic ovary syndrome. Br. J. Obstet. Gynaecol., 100, 365-369.
187. Wada, I., Matson, P.L., Troup, S.A., Morroll, D.R., Hunt, L. and Lieberman, B.A. (1993b) Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition? Br. J. Obstet. Gynaecol., 100, 265-269.
188. Walmer, D.K., Haney, A.F. and Dodson, W.C. (1989) Ovarian hyperstimulation in polycystic ovary syndrome during therapy with leuprolide acetate. Fertil. Steril., 52, 858-859.
189. Whelan, J.G., III and Vlahos, N.F. (2000) The ovarian hyperstimulation syndrome. Fertil. Steril., 73, 883-896.
190. Wu, T.C. (2000) Midcycle administration of single-dose GnRHa for luteal phase failure in women with ovarian hyperstimulation. A report of five cases. J. Reprod. Med., 45, 156-158.